European Medicines Agency Initiates Safety Review of All Intravenous Iron Products
The European Medicines Agency (EMA) has initiated a safety review of all currently available intravenous iron products. This measure was decided following concerns that patients receiving intravenous iron therapy may experience side effects such as hypophosphatemia and osteomalacia.
Hypophosphatemia is a condition where the concentration of phosphate in the blood becomes abnormally low. If this condition persists, it can lead to osteomalacia, a condition characterized by bone weakening and pain, necessitating caution. European health authorities plan to closely investigate the impact of these side effects on patient health.
The scope of this review includes all intravenous iron products authorized within Europe. Experts intend to monitor changes in patients' phosphate levels following the administration of iron and re-evaluate whether existing administration methods are safe.
The Ministry of Food and Drug Safety in South Korea is also closely monitoring this action by Europe. As intravenous iron products are widely used for anemia treatment domestically, there is a possibility that local safety measures or recommendations may change depending on the future results of the European investigation.
Patients should immediately consult with medical staff if they experience abnormal symptoms such as bone pain or muscle weakness after receiving an iron injection. Based on the results of this review, health authorities intend to provide the necessary information to ensure that patients can receive treatment more safely.